{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:01:45Z","timestamp":1793318505286,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Backgrounds<\/jats:title>\n                <jats:p>Clinical evidence of the preventive effectiveness of medium-class topical corticosteroids for capecitabine-induced hand foot syndrome (HFS) is limited. Although the pathogenesis and mechanism of HFS are unclear, inflammatory reactions are thought to be involved in HFS development. This study aimed to evaluate the preventive effect of medium-class topical corticosteroids (hydrocortisone butyrate 0.1% topical therapy) for capecitabine-induced HFS in patients with colorectal cancer receiving adjuvant chemotherapy with capecitabine plus oxaliplatin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a single-center, single-arm, phase 2 study. Patients with colorectal cancer scheduled to receive adjuvant chemotherapy with capecitabine plus oxaliplatin are enrolled, and topical hydrocortisone butyrate 0.1% is applied prophylactically in addition to standard moisturizing therapy. The primary endpoint is the incidence of grade\u2009\u2265\u20092 HFS within three months. The secondary endpoints are the time to onset of HFS, rates of dose reduction, schedule delay, discontinuation caused by capecitabine-induced HFS, and other adverse events. All adverse events are evaluated by clinical pharmacists and attending physicians.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This study is expected to contribute to the establishment of new supportive care for preventing HFS, not only for colorectal cancer patients receiving adjuvant chemotherapy, but also for various cancer patients receiving capecitabine-based chemotherapy.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic>: This trial was registered in the Japan Registry of Clinical Trials (jRCT) as jRCTs031220002. Registered 5 April 2022, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/jrct.niph.go.jp\/search\">https:\/\/jrct.niph.go.jp\/search<\/jats:ext-link><\/jats:p>\n                <jats:p><jats:italic>Protocol version<\/jats:italic> V.1.0, 16 February 2022.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-022-02411-w","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T13:03:50Z","timestamp":1657803830000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study)"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3473-8244","authenticated-orcid":false,"given":"Yohei","family":"Iimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Ahiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Aikou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Shida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Nojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichiro","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"2411_CR1","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1634\/theoncologist.2011-0033","volume":"16","author":"V Sibaud","year":"2011","unstructured":"Sibaud V, Dalenc F, Chevreau C, Roch\u00e9 H, Delord JP, Mourey L, et al. HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist. 2011;16:1469\u201378.","journal-title":"Oncologist"},{"key":"2411_CR2","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","volume":"378","author":"A Grothey","year":"2018","unstructured":"Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, et al. Duration of adjuvant chemotherapy for Stage III colon cancer. N Engl J Med. 2018;378:1177\u201388.","journal-title":"N Engl J Med"},{"key":"2411_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2020.10.480","volume":"32","author":"K Yamazaki","year":"2021","unstructured":"Yamazaki K, Yamanaka T, Shiozawa M, Manaka D, Kotaka M, Gamoh M, et al. Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial. Ann Oncol. 2021;32:77\u201384.","journal-title":"Ann Oncol"},{"key":"2411_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S2468-1253(17)30297-2","volume":"3","author":"T Hamaguchi","year":"2018","unstructured":"Hamaguchi T, Shimada Y, Mizusawa J, Kinugasa Y, Kanemitsu Y, Ohue M, et al. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial. Lancet Gastroenterol Hepatol. 2018;3:47\u201356.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2411_CR5","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1177\/1060028015594451","volume":"49","author":"T Yokokawa","year":"2015","unstructured":"Yokokawa T, Kawakami K, Mae Y, Sugita K, Watanabe H, Suzuki K, et al. Risk factors exacerbating hand-foot skin reaction induced by capecitabine plus oxaliplatin with or without bevacizumab therapy. Ann Pharmacother. 2015;49:1120\u20134.","journal-title":"Ann Pharmacother"},{"key":"2411_CR6","unstructured":"NCCN guidelines colon cancer. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1428."},{"key":"2411_CR7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2147\/PPA.S80327","volume":"9","author":"K Kawakami","year":"2015","unstructured":"Kawakami K, Nakamoto E, Yokokawa T, Sugita K, Mae Y, Hagino A, et al. Patients\u2019 self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis. Patient Prefer Adherence. 2015;9:561\u20137.","journal-title":"Patient Prefer Adherence"},{"issue":"28","key":"2411_CR8","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.3390\/curroncol28050342","volume":"9","author":"S Lakkunarajah","year":"2021","unstructured":"Lakkunarajah S, Breadner DA, Zhang H, Yamanaka E, Warner A, Welch S. The influence of adjuvant chemotherapy dose intensity on five-year outcomes in resected colon cancer: A single centre retrospective analysis. Curr Oncol. 2021;9(28):4031\u201341. https:\/\/doi.org\/10.3390\/curroncol28050342.","journal-title":"Curr Oncol"},{"key":"2411_CR9","first-page":"652","volume":"8","author":"A Degen","year":"2010","unstructured":"Degen A, Alter M, Schenck F, Satzger I, V\u00f6lker B, Kapp A, et al. The hand-foot-syndrome associated with medical tumor therapy\u2014classification and management. J Dtsch Dermatol Ges. 2010;8:652\u201361.","journal-title":"J Dtsch Dermatol Ges"},{"key":"2411_CR10","doi-asserted-by":"publisher","first-page":"796","DOI":"10.3349\/ymj.2009.50.6.796","volume":"50","author":"HS Son","year":"2009","unstructured":"Son HS, Lee WY, Lee WS, Yun SH, Chun HK. Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy. Yonsei Med J. 2009;50:796\u2013802.","journal-title":"Yonsei Med J"},{"key":"2411_CR11","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","volume":"19","author":"E Van Cutsem","year":"2001","unstructured":"Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097\u2013106.","journal-title":"J Clin Oncol"},{"key":"2411_CR12","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","volume":"17","author":"JL Blum","year":"1999","unstructured":"Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17:485\u201393.","journal-title":"J Clin Oncol"},{"key":"2411_CR13","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.21037\/apm-21-61","volume":"10","author":"W Lu","year":"2021","unstructured":"Lu W, Huang Z, Chen S, Lv H, Chen X, Lei J, et al. The effectiveness of EVOSKIN\u00aePalm and sole moisturizing cream in treating capecitabine-associated hand-foot syndrome: a randomized double-blind clinical trial. Ann Palliat Med. 2021;10:3009\u201317.","journal-title":"Ann Palliat Med"},{"key":"2411_CR14","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1200\/JCO.2010.31.1431","volume":"28","author":"SL Wolf","year":"2010","unstructured":"Wolf SL, Qin R, Menon SP, Rowland KM, Thomas S, Delaune R, et al. Placebo-controlled trial to determine the effectiveness of a urea\/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol. 2010;28:5182\u20137.","journal-title":"J Clin Oncol"},{"key":"2411_CR15","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s00432-010-0958-9","volume":"137","author":"RX Zhang","year":"2011","unstructured":"Zhang RX, Wu XJ, Lu SX, Pan ZZ, Wan DS, Chen G. The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II\/III colorectal cancer: a phase II randomized prospective study. J Cancer Res Clin Oncol. 2011;137:953\u20137.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2411_CR16","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1093\/annonc\/mdr400","volume":"23","author":"RX Zhang","year":"2012","unstructured":"Zhang RX, Wu XJ, Wan DS, Lu ZH, Kong LH, Pan ZZ, et al. Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol. 2012;23:1348\u201353.","journal-title":"Ann Oncol"},{"key":"2411_CR17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/ced.12538","volume":"40","author":"SJ Jo","year":"2015","unstructured":"Jo SJ, Shin H, Jo S, Kwon O, Myung SK. Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand-foot syndrome during chemotherapy: a meta-analysis. Clin Exp Dermatol. 2015;40:260\u201370.","journal-title":"Clin Exp Dermatol"},{"key":"2411_CR18","unstructured":"Scheithauer W, Blum J. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. Oncology (Williston Park). 2004 Aug;18:1161\u20138, 1173; discussion 1173\u20136, 1181\u20134."},{"issue":"Suppl 9","key":"2411_CR19","first-page":"19","volume":"14","author":"RB Diasio","year":"2000","unstructured":"Diasio RB. Oral DPD-inhibitory fluoropyrimidine drugs. Oncology (Williston Park). 2000;14(Suppl 9):19\u201323.","journal-title":"Oncology (Williston Park)"},{"key":"2411_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s13577-012-0057-0","volume":"26","author":"N Yokomichi","year":"2013","unstructured":"Yokomichi N, Nagasawa T, Coler-Reilly A, Suzuki H, Kubota Y, Yoshioka R, et al. Pathogenesis of Hand-Foot Syndrome induced by PEG-modified liposomal doxorubicin. Hum Cell. 2013;26:8\u201318.","journal-title":"Hum Cell"},{"key":"2411_CR21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ygyno.2004.05.027","volume":"94","author":"RD Drake","year":"2004","unstructured":"Drake RD, Lin WM, King M, Farrar D, Miller DS, Coleman RL. Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol. 2004;94:320\u20134.","journal-title":"Gynecol Oncol"},{"key":"2411_CR22","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0190-9622(08)80126-0","volume":"24","author":"J Brown","year":"1991","unstructured":"Brown J, Burck K, Black D, Collins C. Treatment of cytarabine acral erythema with corticosteroids. J Am Acad Dermatol. 1991;24:1023\u20135.","journal-title":"J Am Acad Dermatol"},{"key":"2411_CR23","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/(SICI)1097-0142(19980301)82:5<965::AID-CNCR23>3.0.CO;2-Y","volume":"82","author":"PM Hoff","year":"1998","unstructured":"Hoff PM, Valero V, Ibrahim N, Willey J, Hortobagyi GN. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer. 1998;82:965\u20139.","journal-title":"Cancer"},{"key":"2411_CR24","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1046\/j.1365-2133.2002.04864.x","volume":"147","author":"R Van Doorn","year":"2002","unstructured":"Van Doorn R, Kirtschig G, Scheffer E, Stoof TJ, Giaccone G. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol. 2002;147:598\u2013601.","journal-title":"Br J Dermatol"},{"key":"2411_CR25","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","volume":"144","author":"KJ Busam","year":"2001","unstructured":"Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 2001;144:1169\u201376.","journal-title":"Br J Dermatol"},{"key":"2411_CR26","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1111\/j.1365-2133.2005.06885.x","volume":"153","author":"JC Pascual","year":"2005","unstructured":"Pascual JC, Belinch\u00f3n I, Sivera F, Yuste A. Severe cutaneous toxicity following treatment with gefitinib (ZD1839). Br J Dermatol. 2005;153:1222\u20133.","journal-title":"Br J Dermatol"},{"key":"2411_CR27","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","volume":"28","author":"ME Lacouture","year":"2010","unstructured":"Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:1351\u20137.","journal-title":"J Clin Oncol"},{"key":"2411_CR28","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2217\/fon.14.251","volume":"11","author":"Y Kobayashi","year":"2015","unstructured":"Kobayashi Y, Komatsu Y, Yuki S, Fukushima H, Sasaki T, Iwanaga I, et al. Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study. J-STEPP Future Oncol. 2015;11:617\u201327.","journal-title":"J-STEPP Future Oncol"},{"key":"2411_CR29","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s12664-020-01039-6","volume":"39","author":"K Watanabe","year":"2020","unstructured":"Watanabe K, Ishibe A, Watanabe J, Ota M, Fujii S, Ichikawa Y, et al. The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using capecitabine for colorectal cancer: the Yokohama Clinical Oncology Group Study (YCOG1102). Indian J Gastroenterol. 2020;39:204\u201310.","journal-title":"Indian J Gastroenterol"},{"key":"2411_CR30","doi-asserted-by":"publisher","unstructured":"Ostwal V, Kapoor A, Mandavkar S, et al. Effect of a structured teaching module including intensive prophylactic measures on reducing the incidence of capecitabine-induced hand-foot syndrome: results of a prospective randomized Phase III study. Oncologist. 2020 Dec;25:e1886\u201392-e1892. doi: https:\/\/doi.org\/10.1634\/theoncologist.2020-0698.","DOI":"10.1634\/theoncologist.2020-0698"},{"issue":"342","key":"2411_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c7086","volume":"11","author":"S Trelle","year":"2011","unstructured":"Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;11(342): c7086. https:\/\/doi.org\/10.1136\/bmj.c7086.","journal-title":"BMJ"},{"issue":"354","key":"2411_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4857","volume":"28","author":"A Arf\u00e8","year":"2016","unstructured":"Arf\u00e8 A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016;28(354): i4857. https:\/\/doi.org\/10.1136\/bmj.i4857.","journal-title":"BMJ"},{"key":"2411_CR33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1743-7563.2010.01311.x","volume":"6","author":"T Chalermchai","year":"2010","unstructured":"Chalermchai T, Tantiphlachiva K, Suwanrusme H, Voravud N, Sriuranpong V. Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia. Asia Pac J Clin Oncol. 2010;6:155\u201360. https:\/\/doi.org\/10.1111\/j.1743-7563.2010.01311.x.","journal-title":"Asia Pac J Clin Oncol"},{"key":"2411_CR34","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s12282-009-0171-3","volume":"17","author":"N Yoshimoto","year":"2010","unstructured":"Yoshimoto N, Yamashita T, Fujita T, Hayashi H, Tsunoda N, Kimura M, et al. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. Breast Cancer. 2010;17:298\u2013302. https:\/\/doi.org\/10.1007\/s12282-009-0171-3.","journal-title":"Breast Cancer"},{"key":"2411_CR35","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/ced.14486","volume":"46","author":"S Lian","year":"2021","unstructured":"Lian S, Zhang X, Zhang Y, Zhao Q. Pyridoxine for prevention of hand\u2013foot syndrome caused by chemotherapy agents: a meta-analysis. Clin Exp Dermatol. 2021;46:629\u201335. https:\/\/doi.org\/10.1111\/ced.14486.","journal-title":"Clin Exp Dermatol"},{"key":"2411_CR36","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3892\/br.2013.161","volume":"1","author":"Y Zhou","year":"2013","unstructured":"Zhou Y, Peng L, Li Y, Chen L. Prophylactic pyridoxine was not able to reduce the incidence of capecitabine-induced hand-foot syndrome: a meta-analysis. Biomed Rep. 2013;1:873\u20138. https:\/\/doi.org\/10.3892\/br.2013.161.","journal-title":"Biomed Rep"},{"issue":"28","key":"2411_CR37","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1200\/JCO.2010.29.1807","volume":"20","author":"YK Kang","year":"2010","unstructured":"Kang YK, Lee SS, Yoon DH, Lee SY, Chun YJ, Kim MS, et al. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol. 2010;20(28):3824\u20139. https:\/\/doi.org\/10.1200\/JCO.2010.29.1807.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2411_CR38","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1001\/jamaoncol.2017.1269","volume":"1","author":"YS Yap","year":"2017","unstructured":"Yap YS, Kwok LL, Syn N, Chay WY, Chia JWK, Tham CK, et al. Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial. JAMA Oncol. 2017;1(3):1538\u201345. https:\/\/doi.org\/10.1001\/jamaoncol.2017.1269.","journal-title":"JAMA Oncol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02411-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-022-02411-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02411-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T13:06:47Z","timestamp":1657804007000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-022-02411-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2411"],"URL":"https:\/\/doi.org\/10.1186\/s12876-022-02411-w","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]},"assertion":[{"value":"3 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This protocol was reviewed and approved by the certified Clinical Research Review Board of the University of Tokyo (approval number: 2021512SP) prior to conducting the trial. This clinical trial was conducted in compliance with the Clinical Trials Act in Japan and was registered in the Japan Registry of Clinical Trials (jRCT) as jRCTs031220002. All patients will be required to provide written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"341"}}